Interv Akut Kardiol. 2011;10(4):182-186

Is dabigatran a true alternative in preventing thromboembolic complications in patients with atrial fibrillation ?

Kateřina Lefflerová
Klinika kardiologie IKEM

Prevention of thromboembolic complications in patients with atrial fibrillation represents a key therapeutic goal in the care of patients

with this arrhythmia. Anticoagulation therapy with warfarin is capable of reducing the risk of stroke by 64 %. However, treatment with

warfarin is associated with a number of disadvantages, and thus only a portion of patients are treated and not all achieve the therapeutic

range. Dabigatran is a direct thrombin inhibitor administered orally at a fixed dose without a need for monitoring the anticoagulant

effect. Its safety and efficacy in preventing stroke and systemic embolization in patients with atrial fibrillation has been demonstrated

in the RE-LY study.

Keywords: atrial fibrillation, prevention of thromboembolism, anticoagulant therapy, dabigatran

Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lefflerová K. Is dabigatran a true alternative in preventing thromboembolic complications in patients with atrial fibrillation ? Interv Akut Kardiol. 2011;10(4):182-186.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375. Go to original source... Go to PubMed...
    2. Gersh BJ, Tsang TSM, Seward JB. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. Transactions Am Clin Climatol Assoc 2004; 116: 149-160.
    3. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke. Results from a population-based study. Stroke 2005; 36: 1115-1119. Go to original source... Go to PubMed...
    4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867. Go to original source... Go to PubMed...
    5. Nieuwlaat R, Capucci A, Lip GIH, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026. Go to original source... Go to PubMed...
    6. Weitz IJ, Hirsh J, Samama MM. New antithrombotic drugs*: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 234S-246S. Go to original source...
    7. Schirmer SH, Baumhackel M, Neuberger HR, et al. Novel anticoagulants for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2010; 56: 2067-2076. Go to original source... Go to PubMed...
    8. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003; 362: 1691-1698. Go to original source... Go to PubMed...
    9. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-698. Go to original source... Go to PubMed...
    10. Stangier J. Clinical pharmacokinetics and pharmacodynamics of oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295. Go to original source... Go to PubMed...
    11. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127. Go to original source... Go to PubMed...
    12. Van Ryn J, Litzenburger T, Waterman A, et al. Dabigatran anticoagulant aktivity is neutralized by an antipody selective to dabigatran in vitro and in vivo models. J Am Coll Cardiol 2011; 57, poster board No 1142-1367. Go to original source...
    13. Eriksson BI, Dahl OE, Rosencher N, et al., RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-956. Go to original source... Go to PubMed...
    14. Eriksson BI, Dahl OE, Rosencher N, et al., RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5(11): 2178-2185. Go to original source... Go to PubMed...
    15. Friedman RJ, Dahl OE, Rosencher N, et al., RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010; 126(3): 175-182. Go to original source... Go to PubMed...
    16. Schulman S, Kearon C, Kakkar et al., RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24): 2342-2352. Go to original source... Go to PubMed...
    17. Oldgren J, Budaj A, Granger CB, et al. Randomized dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel (RE-DEEM). Circulation 2009; 120: abstrakt 165. Go to PubMed...
    18. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007; 100(9): 1419-1426. Go to original source... Go to PubMed...
    19. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876. Go to original source... Go to PubMed...
    21. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983. Go to original source... Go to PubMed...
    22. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versusu warfarin in patiens with atrial fibrillation. An analysis of patients undergoing cardioversion. Circulation. 2011; 123: 131-136. Go to original source... Go to PubMed...
    23. Gage BF. Can we rely on RE-LY? N Engl J Med 2009; 361: 1200-1202. Go to original source... Go to PubMed...
    24. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann. Intern. Med. 2011; 154(1): 1-11. Go to original source... Go to PubMed...
    25. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429. Go to original source... Go to PubMed...
    26. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/ HRS Focused Update on the management of Patients With Atrial Fibrillation (Update on Dabigatran). J Am Coll Cardiol 2011; doi: 10.1016/j. jacc. 2011.01.010.
    27. Cairns S, Connolly S, Mc Murtry S, et al. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011; 27: 74-90. Go to original source... Go to PubMed...
    28. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 April 2011. http://www.ema.europa.eu/ema/index.jsp?curl=page/news_and_events/news/2011/04/news_detail001243.2011.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.